Her-2 prognostic value in very early-stage breast cancer: A single-institution retrospective analysis

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 459-465

  Sanpaolo, Pietro ^a   Barbieri, Viviana ^a   Pedicini, Piernicola ^a   Fusco, Vincenzo ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Conservative therapy; Early stage breast cancer; Her 2 neu oncogene; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; AGED; BREAST TUMOR; CLINICAL TRIAL; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84866268747     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9869-0     Document Type: Article

References (37)

1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosinekinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science. 1985;230:1130-9.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer. Correlation of relapse and survival with amplification of the Her- 2/neu oncogene. Science. 1987;235:177-82.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
4. Raudin PM, Chamness GC. The c-erbB-2 protooncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. A review. Gene. 1995;159:19-27.
5. Budzar A, Ibrahim NK, Francio D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy. Results of a randomized trial in human epidermal growth factor receptor-2 positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
6. Joensuu H, Kellolumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-20.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her 2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
8. Ramond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her 2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
9. Slamon DJ, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her-2/neu positive early breast cancer patients. 29th San Antonio Breast Cancer Symposium 2006; 14-17.
10. Gonzalez-Angulo AM, Litton JK, Broglio R, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-6.
11. Press MF, Bernstein L, Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894-904.
12. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9(3):223-30.
13. Black D, Younger J, Martei Y. Recurrence risk in T1a-b, nodenegative, HER2 positive breast cancer. Breast Cancer Res Treat 2006; 100: (Abst 2037): s92.
14. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26(35):5697-704.
15. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693-9.
16. ICRU. Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: International Commission on Radiation Units and Measurements; 1999.
17. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the Her-2/neu gene and protein. Mol Cell Proteom. 2004;3:379-98.
18. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47:28-51.
19. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-56.
20. McKinnel RG. Metastasis. In: McKinnel RG, Parchment RE, Perantoni AO, editors. The biological basis of cancer. New York: Cambridge University Press; 1998. p. 50-78.
21. Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patient's overall and diseasefree survival. Br J Cancer. 1997;75:1667-73.
22. O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-63.
23. Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12:23-8.
24. Climent MA, Segui MA, Peirò G, et al. Prognostic value of Her- 2/neu and p53 expression in node-positive breast cancer. Her-2/neu effect on adjuvant tamoxifen treatment. The Breast. 2001;10:67-77.
25. Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone or in combination with other prognostic factors. J Clin Oncol. 1998;16:462-9.
26. Swede H, Moysich KB, Winston JS, et al. Variation of the prognostic significance of Her-2 expression in breast cancer according to tumor size. Breast J. 2003;9:98-105.
27. Smith I, Procter M, Gelber RD, et al. 2-year follows up of trastuzumab after adjuvant chemotherapy in Her-2 positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
28. Sidoni A, Cavaliere A, Bellezza G, et al. Breast cancer in young women: clinicopathological features and biological specificity. The Breast. 2003;12:247-50.
29. Zavagno G, Meggiolaro F, Pluchinotta A, et al. Influence of age and menopausal status on pathologic and biologic features of breast cancer. The Breast. 2000;9:320-8.
30. Daidone MG, Cordini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45:313-25.
31. Wollman R, Yahalom J, Maxy R, et al. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994;30:91-8.
32. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884-90.
33. Liang K, Lu Y, Jin W, et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2:1113-20.
34. She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res. 2003;9: 3773-8.
35. Pietras RJ, Poen JC, Galardo D, et al. Monoclonal antibody to Her- 2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347-55.
36. Bucholz TA, Huang EH, Berru D, et al. Her-2 positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:1337-42.
37. Harris EER, Hwang WT, Lee EA, et al. The impact of Her-2 status on local recurrence rate in women with stage I-II breast cancer treated with breast conserving therapy. Breast J. 2006;12(5):431-6.